ライフサイエンスコーパス: disopyramide

1 heart rate was increased in the presence of disopyramide.

2 73 obstructive HCM patients not treated with disopyramide.

3 h as estradiol, pirenperone, loperamide, and disopyramide.

4 We studied the open-channel blockers disopyramide and flecainide, and the lidocaine derivativ

5 All-cause annual cardiac death rate between disopyramide and non-disopyramide-treated patients did n

6 4%) could not be satisfactorily managed with disopyramide and required major invasive interventions b

7 The antiarrhythmic agent disopyramide and various serotonin reuptake blockers hav

8 xertional dyspnea (beta-blockers, verapamil, disopyramide) and the septal myotomy-myectomy operation,

9 everal antiarrhythmic drugs such as sotalol, disopyramide, and amiodarone, can be effective in suppre

10 ence was strong for amiodarone, propafenone, disopyramide, and sotalol.

11 in 118 obstructive HCM patients treated with disopyramide at 4 HCM treatment centers.

12 tor complexity. Application of quinidine and disopyramide, but not sotalol, normalized APD and suppre

13 irds of obstructed HCM patients treated with disopyramide could be managed medically with amelioratio

14 In wild-type channels, 100 microM disopyramide decreased mean open time from 1.64 +/- 0.08

15 pulses at 150-ms interpulse intervals during disopyramide exposure.

16 Patients were followed with disopyramide for 3.1 +/- 2.6 years; dose 432 +/- 181 mg/

17 ssessed the long-term efficacy and safety of disopyramide for patients with obstructive hypertrophic

18 However, long-term efficacy and safety of disopyramide has not been shown in a large cohort.

19 mortality through stepped management, adding disopyramide in appropriately selected patients, and whe

20 suggest the detection of new metabolites of disopyramide in the population samples.

21 We concluded that disopyramide may be a desirable choice in reversing the

22 It has been reported that disopyramide may reduce left ventricular outflow gradien

23 rophysiological testing on quinidine (n=54), disopyramide (n=2), or both (n=4).

24 zed specific mutation, open-channel block by disopyramide persists.

25 gents for rhythm maintenance are amiodarone, disopyramide, propafenone, and sotalol (drugs listed in

26 Disopyramide therapy does not appear to be proarrhythmic

27 diac death rate between disopyramide and non-disopyramide-treated patients did not differ significant

28 Mortality in the disopyramide-treated patients was compared with 373 obst

29 Disopyramide was added in 221 (74%) patients and pharmac

30 ydropyridine calcium-channel blocker, and/or disopyramide) were eligible for protocol-guided SoC down

31 ty-eight patients (66%) were maintained with disopyramide without the necessity for major non-pharmac